Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Granuloma Annulare and Cutaneous Sarcoidosis
NCT06725264Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucravacitinib in granuloma annulare (GA), cutaneous sarcoidosis, sponsored by Yale University. Planned start Mar 2025; status: withdrawn.
02
Drugs
deucravacitinib
03
Conditions
granuloma annulare (GA)cutaneous sarcoidosis
Beyond the preview
Go deeper on NCT06725264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725264.